Litigation Details for Auxilium Pharmaceuticals v. Upsher-Smith Laboratories (Fed. Cir. 2014)

Auxilium Pharmaceuticals v. Upsher-Smith Laboratories (Fed. Cir. 2014)

Docket		Date Filed	2014-01-29
Court	Court of Appeals for the Federal Circuit	Date Terminated	2014-09-18
Cause		Assigned To
Jury Demand		Referred To
Patents	6,503,894; 7,320,968; 7,608,605; 7,608,606; 7,608,607; 7,608,608; 7,608,609; 7,608,610; 7,935,690; 8,063,029; 8,178,518
Link to Docket	External link to docket

Details for Auxilium Pharmaceuticals v. Upsher-Smith Laboratories (Fed. Cir. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-01-29				External link to document

Auxilium Pharmaceuticals v. Upsher-Smith Laboratories, 14-1268: Litigation Summary and Patent Analysis

Last updated: September 8, 2026

Auxilium Pharmaceuticals prevailed against Upsher-Smith in a Federal Circuit appeal involving AndroGel 1% and U.S. Patent No. 6,503,894. The court affirmed the district court’s judgment that the asserted claims were not invalid for obviousness and that Upsher-Smith’s proposed generic testosterone gel infringed the patent. The decision preserved Auxilium’s patent barrier to FDA approval of the accused ANDA product until the ’894 patent expired in 2020. Auxilium Pharms., Inc. v. Upsher-Smith Labs., Inc., 770 F.3d 1305 (Fed. Cir. 2014).

The case was a Hatch-Waxman patent dispute concerning a topical testosterone formulation. It did not involve biologic substitution, biosimilar approval, or patent settlement terms.

What patents protected AndroGel 1% in Auxilium v. Upsher-Smith?

The central patent was U.S. Patent No. 6,503,894, assigned to Unimed Pharmaceuticals, Inc., an Auxilium affiliate. The patent covered pharmaceutical testosterone gel compositions and their transdermal use.

Item	Detail
Patent	U.S. Patent No. 6,503,894
Patent title	Testosterone gel formulations and methods of use
Patent owner or associated holder	Unimed Pharmaceuticals, Inc., later associated with Auxilium Pharmaceuticals
Product	AndroGel 1%
Active ingredient	Testosterone
Dosage form	Topical hydroalcoholic gel
FDA product	AndroGel 1%, NDA No. 021015
Federal Circuit docket	No. 14-1268
Federal Circuit decision	2014
Reported citation	770 F.3d 1305
Patent expiration	August 27, 2020, according to FDA Orange Book patent data
Main legal issues	Claim construction, infringement, obviousness, secondary considerations

The patent claimed a testosterone formulation using a hydroalcoholic vehicle and penetration-enhancing components. The technology was intended to deliver testosterone through the skin following application to specified body areas, including the shoulders and upper arms.

The patent’s commercial value came from the combination of composition claims and method-of-use claims. A generic manufacturer could not avoid the patent merely by copying the active ingredient. The formulation and administration method also formed part of the infringement analysis.

What was the dispute in Auxilium Pharmaceuticals v. Upsher-Smith?

Upsher-Smith submitted an abbreviated new drug application seeking FDA approval for a generic testosterone gel. Auxilium sued under the Hatch-Waxman Act after receiving notice of Upsher-Smith’s Paragraph IV certification.

Upsher-Smith argued that the asserted claims were invalid, principally because the claimed formulation and method would have been obvious in view of earlier testosterone formulations and transdermal delivery disclosures. Auxilium argued that the prior art did not provide a sufficient reason to combine the relevant ingredients or predict the claimed performance.

The district court conducted a bench trial in the District of Delaware. It found that the asserted claims were not invalid for obviousness and that Upsher-Smith’s proposed product infringed. Upsher-Smith appealed to the Federal Circuit.

The Federal Circuit affirmed the judgment.

How did the Federal Circuit decide the obviousness challenge?

The Federal Circuit held that the district court did not clearly err in finding the claims nonobvious. The ruling applied the established framework under 35 U.S.C. § 103, considering:

1. The scope and content of the prior art.
2. Differences between the prior art and the asserted claims.
3. The level of ordinary skill in the art.
4. Objective evidence of nonobviousness.

The court treated the prior art as relevant but insufficient to establish that a skilled artisan would have selected and combined the claimed ingredients with a reasonable expectation of success.

The decision emphasized the distinction between identifying individual claim elements in separate references and establishing an articulated reason to combine those elements. The presence of testosterone gels and known penetration enhancers in the prior art did not automatically make the claimed formulation obvious.

The district court also credited objective evidence supporting nonobviousness, including unexpected results and commercial success. The Federal Circuit deferred to the district court’s factual findings because the case had been tried without a jury.

What role did unexpected results play?

The evidence concerned the formulation’s ability to deliver testosterone through the skin at therapeutically useful levels. Auxilium presented data showing that the claimed formulation performed better than certain prior formulations.

The courts did not treat commercial success or performance data as independently dispositive. They considered the evidence as part of the full obviousness record. The Federal Circuit concluded that the district court was entitled to weigh the objective evidence in Auxilium’s favor after finding a sufficient nexus between the evidence and the claimed formulation.

What infringement issues did the court address?

The case concerned whether Upsher-Smith’s ANDA product fell within the scope of the asserted claims. Under the Hatch-Waxman framework, the relevant inquiry focused on the product described in the ANDA rather than ordinary commercial marketing.

The district court found infringement. The Federal Circuit affirmed the judgment after reviewing the claim construction and infringement findings.

The formulation claims were significant because the proposed generic product allegedly contained the same or materially corresponding functional components required by the asserted claims. The method claims also created risk because the ANDA labeling directed use in a manner corresponding to the patented administration method.

An ANDA applicant cannot avoid infringement by omitting instructions from the label when the proposed labeling otherwise encourages the patented use. The analysis is governed by the ANDA product and its intended use, not merely by a generic manufacturer’s characterization of its commercial plans.

When did the ’894 patent lose exclusivity?

The ’894 patent expired on August 27, 2020. That date marked the end of the patent-based exclusionary period identified in FDA Orange Book records.

Exclusivity event	Date or result
ANDA Paragraph IV dispute	Led to federal patent litigation
District court judgment	Auxilium prevailed
Federal Circuit decision	2014; judgment affirmed
Patent expiration	August 27, 2020
Current patent status	Expired
Post-expiration patent barrier	None based on the ’894 patent

The expiration date is distinct from FDA regulatory exclusivity. A patent expiration does not itself guarantee immediate generic approval. FDA approval also depends on the ANDA’s scientific, manufacturing, labeling, and regulatory status. The patent-specific litigation barrier, however, ended when the patent expired.

What was the Orange Book status of AndroGel 1%?

AndroGel 1% was listed in FDA’s Orange Book with the ’894 patent as an associated patent. The listing supported Auxilium’s Hatch-Waxman enforcement action after Upsher-Smith filed its ANDA.

The Orange Book listing did not establish validity or infringement. Those questions were decided in federal court. The listing provided the regulatory mechanism through which a Paragraph IV certification could trigger patent litigation and the statutory 30-month stay of FDA approval.

The case illustrates the commercial importance of Orange Book formulation and method-of-use listings. A drug can remain exposed to generic competition even when its active ingredient is old, provided enforceable patents cover the finished formulation or an approved use.

Did Upsher-Smith file a Paragraph IV challenge?

Yes. Upsher-Smith’s ANDA included a Paragraph IV certification challenging the ’894 patent. Auxilium responded with an infringement action under 35 U.S.C. § 271(e)(2).

The Paragraph IV filing created the jurisdictional basis for the litigation. It also initiated the statutory regulatory stay associated with the patent challenge. The Federal Circuit’s affirmance left the patent enforceable against the accused ANDA product until expiration.

The case did not invalidate the patent, narrow the patent sufficiently to permit the accused product, or produce an appellate ruling authorizing early entry.

What patent litigation affected AndroGel generic entry?

The principal case was the District of Delaware action between Auxilium and Upsher-Smith, followed by Federal Circuit appeal No. 14-1268.

Litigation stage	Outcome
ANDA filing	Upsher-Smith challenged the ’894 patent under Paragraph IV
District of Delaware trial	Auxilium prevailed on validity and infringement
Federal Circuit appeal	Upsher-Smith appealed
Federal Circuit ruling	District court judgment affirmed
Settlement agreement	No settlement disposition was reported in the appellate decision
Final patent result	’894 patent remained enforceable through expiration

The appellate decision did not create a new standard for pharmaceutical patent validity. Its business impact came from preserving an existing patent against a proposed generic product during the remaining patent term.

How strong was the Auxilium patent estate?

The ’894 patent was strong enough to survive a full obviousness challenge and support an infringement judgment against the ANDA product. Its practical strength came from four factors:

• It covered a commercially important testosterone gel formulation.
• It included composition and method-of-use protection.
• Auxilium produced evidence of formulation performance and commercial success.
• The district court made favorable factual findings that received deference on appeal.

The estate was not invulnerable. The asserted claims faced a substantial prior-art challenge, and the Federal Circuit’s affirmance depended heavily on the district court’s factual assessment of motivation to combine, reasonable expectation of success, and objective evidence.

After August 2020, the patent ceased to provide an exclusionary basis against generic entry.

Did the case involve biosimilar risk?

No. AndroGel is a small-molecule testosterone product, not a biologic. Upsher-Smith pursued an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k) of the Public Health Service Act.

The relevant competitive risks were generic formulation and labeling challenges, not biosimilar interchangeability or biologic patent dance procedures.

What generic launch risks existed after the ruling?

Before patent expiration, Upsher-Smith faced the following risks:

1. FDA approval could remain blocked during the statutory stay and patent term.
2. Commercial launch could expose the company to damages or injunction risk if the product infringed.
3. A failed validity challenge could preserve the branded product’s market position.
4. A launch before patent expiry could create additional litigation and regulatory exposure.

After patent expiration, the primary barriers shifted from patent law to FDA approval, manufacturing readiness, supply, pricing, and market access.

For Auxilium, revenue exposure was concentrated in AndroGel sales during the remaining patent term. The litigation protected that revenue stream against the specific Upsher-Smith product but did not prevent other generic manufacturers from pursuing separate regulatory and patent strategies after expiration.

How does Auxilium v. Upsher-Smith compare with a typical generic patent case?

The case was typical in procedure but important in its treatment of formulation patents.

Issue	Auxilium v. Upsher-Smith
Product type	Small-molecule topical gel
Regulatory pathway	ANDA
Patent challenge	Paragraph IV
Core patent type	Formulation and method-of-use
Main validity issue	Obviousness
Trial format	Bench trial
Appellate posture	Review of factual findings for clear error
Result	Patent upheld; infringement affirmed
Market effect	Generic entry remained constrained until patent expiration

The case also shows why formulation patents can have commercial value after active-ingredient patents have expired. A manufacturer may face infringement exposure from the delivery vehicle, penetration enhancer, dosage concentration, application site, or label even when testosterone itself is unpatented or long established.

Key Takeaways

• Auxilium prevailed against Upsher-Smith in the AndroGel 1% Paragraph IV litigation.
• The Federal Circuit affirmed the ’894 patent’s validity and the finding of infringement.
• The principal issues were obviousness, claim scope, formulation technology, and transdermal administration.
• The ’894 patent expired on August 27, 2020.
• The case involved an ANDA, not a biosimilar application.
• The ruling preserved the patent barrier against Upsher-Smith’s accused generic product during the remaining patent term.
• After expiration, patent risk ended, while FDA approval and commercial execution remained relevant to generic entry.

FAQs

What was the patent number in Auxilium Pharmaceuticals v. Upsher-Smith?

The principal patent was U.S. Patent No. 6,503,894, covering testosterone gel formulations and methods of use.

What product was protected by the Auxilium patent?

The patent was associated with AndroGel 1%, a topical testosterone gel marketed by Auxilium and its affiliates.

Did Upsher-Smith invalidate the AndroGel patent?

No. The district court found the asserted claims nonobvious and infringed, and the Federal Circuit affirmed.

Was the Auxilium patent still active after 2020?

No. The ’894 patent expired on August 27, 2020.

Did the case establish a biosimilar precedent?

No. The dispute involved a small-molecule ANDA and a Paragraph IV certification, not a biologic or biosimilar application.

References

1. Auxilium Pharmaceuticals, Inc. v. Upsher-Smith Laboratories, Inc., 770 F.3d 1305 (Fed. Cir. 2014).

2. U.S. Patent No. 6,503,894. (2003). Testosterone gel formulations and methods of use.

3. U.S. Food and Drug Administration. (2020). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. Hatch-Waxman Amendments, Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

5. 35 U.S.C. § 271(e)(2) (2024).